{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-062192","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.427653+00:00","generated_at":"2026-05-18T08:59:17.730464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared","bullets":["Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.","Twelve-month sales ended June 30, 2025 were $28.3M, up 22% YoY from $23.2M.","Order backlog reduced to under $100k as of June 30, 2025, down from $3.4M on May 6.","Evaluating additional capacity investments to increase production capacity to ~$40M per year.","Conference call scheduled for August 15, 2025 to discuss full Q2 2025 financial results."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-062192","json":"https://secwatch.observer/filing/0001213900-25-062192.json","markdown":"https://secwatch.observer/filing/0001213900-25-062192.md","text":"https://secwatch.observer/filing/0001213900-25-062192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/0001213900-25-062192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/ea0248347-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:59:17.730464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}